Characterization of the long-term pharmacokinetics of bevacizumab following last dose in patients with resected stage II and III carcinoma of the colon

A multicenter, randomized, open-label study to assess the steady-state pharmacokinetics of bevacizumab given with either XELOX or FOLFOX-4 in patients with metastatic colorectal cancer

(2011) Jianguo Zhi et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Antiangiogenic Agents in Combination with Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer

(2011) Susanna V. Ulahannan et al.   CANCER INVESTIGATION

Targeted therapy with bevacizumab (Avastin) for metastatic colorectal cancer

(2011) Georgios V. Koukourakis et al.   Clinical & Translational Oncology

Vascular Endothelial Growth Factor-Targeted Therapy for the Treatment of Renal Cell Carcinoma

(2011) Bernard Escudier et al.   DRUGS

The role of bevacizumab in colorectal cancer: understanding its benefits and limitations

(2011) Karen Mulder et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Irinotecan and bevacizumab in recurrent glioblastoma multiforme

(2011) Jan Nyrop Jakobsen et al.   EXPERT OPINION ON PHARMACOTHERAPY

Bevacizumab in non-small-cell lung cancer: a review

(2011) David Planchard   Expert Review of Anticancer Therapy

Serum albumin concentration: a predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis

(2011) A.A. Fasanmade et al.   INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS

Bevacizumab: current updates in treatment

(2010) Margaret EM Van Meter et al.   CURRENT OPINION IN ONCOLOGY

Inhibiting the VEGF–VEGFR pathway in angiosarcoma, epithelioid hemangioendothelioma, and hemangiopericytoma/solitary fibrous tumor

(2010) Min S Park et al.   CURRENT OPINION IN ONCOLOGY

Treatment of advanced pancreatic cancer: From gemcitabine single agent to combinations and targeted therapy

(2009) Fernando Rivera et al.   CANCER TREATMENT REVIEWS

Clinical pharmacokinetics of bevacizumab in patients with solid tumors

(2008) Jian-Feng Lu et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY